Patents Issued in June 25, 2024
  • Immunomodulatory compositions comprising microbial entities
    Patent number: 12016891
    Abstract: This disclosure provides for compositions (e.g., pharmaceutical compositions, dietary supplements, medical foods and food stuff), comprising combinations of live microbe populations for the treatment and/or prevention of immune system disorders and conditions related to inflammation, including both pathogen assisted conditions and conditions that are independent of pathogens. Included with the present disclosure are methods for use of the compositions, and methods for selecting microbial entities to formulate the compositions of the disclosure.
    Type: Grant
    Filed: April 20, 2023
    Date of Patent: June 25, 2024
    Assignee: SOLAREA BIO, INC.
    Inventors: Eric Michael Schott, Gerardo V. Toledo, Maria Juliana Soto-Giron, Alicia Eve Ballok, Ryan Green, Mark Charbonneau
  • Bacteriophages for treatment of tuberculosis
    Patent number: 12016892
    Abstract: Disclosed are pharmaceutical compositions comprising a combination of five or more phages and a pharmaceutically acceptable carrier, as well as methods of treating, reducing, or preventing a disease caused by Mycobacterium tuberculosis in a mammal, methods of treating an antibiotic resistant infection in a mammal, and methods of treating, reducing, or preventing activation of a latent disease caused by M. tuberculosis.
    Type: Grant
    Filed: April 8, 2022
    Date of Patent: June 25, 2024
    Assignee: University of Pittsburgh the Commonwealth System of Higher Education
    Inventors: Graham F. Hatfull, Carlos Andrés Guerrero, Rebekah Marie Dedrick
  • Oncolytic viruses for modified MHC expression
    Patent number: 12016893
    Abstract: The present disclosure provides for recombinant oncolytic viruses with gene deletions or insertions which result in downregulation of Major Histocompatibility Complex class I and alternatively or additively upregulation of Major Histocompatibility Complex class II. Immunologic and pharmaceutical compositions comprising these recombinant viruses and methods of using these compositions are also presented.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: June 25, 2024
    Assignee: KaliVir Immunotherapeutics, Inc.
    Inventors: Stephen Howard Thorne, Mingrui Zhang
  • Composition for use in the prevention and/or treatment of the genitourinary mucosa
    Patent number: 12016894
    Abstract: The present invention refers to a composition for use in the prevention and/or treatment of a medical condition affecting the urogenital mucosa. It also refers to the use of said composition for preparing a medicament for the prevention and/or treatment of said condition. Furthermore, it refers to a method of preventing and/or treating said condition in which said composition is administered to a subject in need thereof.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: June 25, 2024
    Assignee: MUCOSA INNOVATIONS, S.L.
    Inventor: Deborah Rodriguez Vilaboa
  • Skin care formulation
    Patent number: 12016895
    Abstract: A method of treating telangiectasia in a subject in need thereof is disclosed. The method includes topically applying to skin of said subject in need of treatment of telangiectasia a composition comprising effective amounts of an extract of Centella asiatica leaf and an extract of Vitis vinifera seed to disrupt endothelial tubes in skin.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: June 25, 2024
    Assignee: MARY KAY INC.
    Inventor: Tiffany Carle
  • Dipeptidomimetics as inhibitors of human immunoproteasomes
    Patent number: 12016896
    Abstract: The compounds of the present invention are represented by the following compounds having Formula I: where the substituents R1, R4, L, M, X, Y, and s are as defined herein. The compounds of the present invention are also represented by the following compounds having Formula (Ia), Formula (Ib), or Formula (Ic): where the substituents R1-R4, Rx, Ry, X, Y, and s are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders or for providing immunosuppression for transplanted organs or tissues.
    Type: Grant
    Filed: November 22, 2021
    Date of Patent: June 25, 2024
    Assignee: CORNELL UNIVERSITY
    Inventors: Gang Lin, Carl Nathan, Pradeep K. Singh
  • Microparticles containing leuprolide and method for producing the same
    Patent number: 12016897
    Abstract: The present invention provides microparticles containing leuprolide and a method for producing the same. When the microparticles are administered by injection, they may lower pain due to their small size, control the release rate of leuprolide at a target site, prevent excessive release of leuprolide at an initial stage, enable exposure to a sufficient amount of the drug to exhibit the effect of leuprolide, and exhibit the effect of leuprolide for 1 month or more. The present invention also provides a method for producing microparticles, in which the microparticles have a uniform particle size and a smooth surface and may exhibit the effect of releasing leuprolide sustainably over a long period of time.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: June 25, 2024
    Assignee: INVENTAGE LAB INC.
    Inventors: Ju Hee Kim, Min Sung Kim
  • Compositions and uses of antimicrobial materials with tissue-compatible properties
    Patent number: 12016898
    Abstract: Compositions comprising a mixture of an antimicrobial cationic polypeptide and a second pharmaceutically-acceptable polymer are disclosed, as well as methods and uses thereof for the treatment and prevention of infections that occur when our natural barriers of defense are broken.
    Type: Grant
    Filed: March 1, 2022
    Date of Patent: June 25, 2024
    Assignee: Amicrobe, Inc.
    Inventors: Michael P. Bevilacqua, Diego Benitez, Jarrod A. Hanson
  • Compositions comprising Sel1-derived peptides and methods of treatment/prevention of excess oxalate levels and associated conditions/diseases therewith
    Patent number: 12016899
    Abstract: Provided herein are compositions comprising Sel1-derived peptides thereof, and method of use thereof for the treatment/prevention excess oxalate levels and conditions and diseases related thereto. In particular, peptides comprise Sel-like repeat (SLR) domains and/or tetratricopeptide (TPR) domains and may be linked together or with other peptides or polypeptides to treat/prevent diseases/conditions related to excess oxalate levels, such as hyperoxaluria and/or hyperoxalemia.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: June 25, 2024
    Assignee: The University of Chicago
    Inventors: Hatim A. Hassan, Donna Arvans
  • Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent
    Patent number: 12016900
    Abstract: A method is provided for treating a cancer patient non-responsive to treatment with a immune checkpoint inhibitor (ICI) by treating the patient with said ICI in combination with an agent that blocks the activity of a dominant factor selected among the plurality of host-driven resistance factors generated in response to treatment of the cancer patient with the ICI, these factors having a fold-change predictive of a non-favorable response of the cancer patient to the treatment with the ICI.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: June 25, 2024
    Assignee: Rappaport Family Institute for Research in the Medical Sciences
    Inventor: Yuval Shaked
  • Tissue catalyzed growth of polymer as epithelial linings for therapy
    Patent number: 12016901
    Abstract: The present disclosure provides compositions, methods, and kits that enable the in situ growth of polymers on or within a subject. In some aspects, the monomer, dopamine, polymerizes in vivo to form a polymer on a tissue. In additional aspects, the compositions, methods, and kits are useful for treating or preventing a disease or disorder.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: June 25, 2024
    Assignees: Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: Robert S. Langer, Carlo Giovanni Traverso, Junwei Li, Thomas Wang, Ameya R. Kirtane, Yunhua Shi
  • Biologic for the treatment of cancer
    Patent number: 12016902
    Abstract: In one aspect, methods of treating a subject having a cancer that expresses a cytokine receptor are provided. In some embodiments, the method comprises administering to the subject a biologic agent in an amount sufficient to induce loss of cytokine receptor signaling through increased expression of a Suppressor of Cytokine Signaling genes and/or loss of one or more cytokine receptor components from the cancer cell surface. In some embodiments, the biologic agent is a cytokine or cytokine mimetic.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: June 25, 2024
    Assignee: LOMA LINDA UNIVERSITY
    Inventors: Kimberly J. Payne, Olivia L. Francis-Boyle
  • Long-acting growth hormone treatment
    Patent number: 12016903
    Abstract: The present invention relates a pharmaceutical formulation comprising a long-acting growth hormone for use in a method of treating growth hormone deficiency, wherein the long-acting growth hormone formulation is administered to a patient in a bracketed dosage regimen, to a multitude of unit dosage forms comprising a long-acting growth hormone formulation, wherein the unit dosage forms comprise increasing amounts of growth hormone equivalents and wherein the amount of growth hormone equivalents increases by at least 10% between one unit dosage form and the next higher dosage form; their use in a method of treating growth hormone deficiency and method of treating growth hormone deficiency in a bracketed dosing regimen.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: June 25, 2024
    Assignee: ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S
    Inventors: Kennett Sprogøe, Henrik Egesborg, Steen Jensen, Thomas Kurpiers
  • Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
    Patent number: 12016904
    Abstract: The present invention relates to a method for treating gastrointestinal bleeding in a subject with severe von Willebrand Disease comprising administering to the subject at least one dose of recombinant von Willebrand Factor (rVWF) ranging from about 40 IU/kg to about 100 IU/kg, wherein the first dose further comprises recombinant Factor VIII (rFVIII).
    Type: Grant
    Filed: December 6, 2022
    Date of Patent: June 25, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Miranda Chapman, Bruce Ewenstein, Bettina Ploder
  • Pharmaceutical composition for prevention or treatment of preterm birth
    Patent number: 12016905
    Abstract: Disclosed is a pharmaceutical composition for the prevention or treatment of preterm birth, comprising, as an active ingredient, an agent that inhibits the differentiation of fibroblasts into myofibroblasts in cervix.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: June 25, 2024
    Assignee: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
    Inventors: Ki Hoon Ahn, Eun Jin Wang
  • Pharmaceutical composition for anaemia
    Patent number: 12016906
    Abstract: The present invention relates to a pharmaceutical composition/formulation for use in treatment of Iron Deficiency Anaemia (IDA), Anaemia of Inflammation (AOI) and neuro-degenerative disorders. More particularly, the invention relates to a pharmaceutical composition/formulation comprising a synergistic combination of Lactoferrin and Guanosine Nucleotides or a pharmaceutically acceptable salt thereof. The application also provides various formulations and methods of preparing the same.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: June 25, 2024
    Assignee: Frimline Private Limited
    Inventors: Ankit Shyam Singh, Vedprakash Mishra, Neelima Tongra
  • Stable thermolysin hydrogel
    Patent number: 12016907
    Abstract: Disclosed is a hydrogel comprising a hydrophilic gelling agent that includes a nonionic cellulose ether, and active thermolysin, wherein the proteolytic activity of the thermolysin does not decrease by more than 20% when stored at room temperature for 6 months.
    Type: Grant
    Filed: August 15, 2022
    Date of Patent: June 25, 2024
    Assignee: SMITH & NEPHEW, INC.
    Inventors: Lei Shi, Aleksa Jovanovic, Dennis Carson
  • Compositions and methods for treating hemoglobinopathies
    Patent number: 12016908
    Abstract: The present invention features compositions and methods for editing deleterious mutations associated with hemoglobinopathies, such as sickle cell disease (SCD). In particular embodiments, the invention provides methods for correcting mutations in a beta globin polynucleotide using modified adenosine base editors termed “ABE8” having unprecedented levels (e.g., >60-70%) of efficiency.
    Type: Grant
    Filed: July 26, 2022
    Date of Patent: June 25, 2024
    Assignee: Beam Therapeutics Inc.
    Inventors: Ian Slaymaker, Nicole Gaudelli, Yi Yu, Bernd Zetsche, David A. Born, Seung-Joo Lee, Michael Packer
  • Regulatory T cell epitopes, compositions and uses thereof
    Patent number: 12016909
    Abstract: The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.
    Type: Grant
    Filed: April 21, 2021
    Date of Patent: June 25, 2024
    Assignee: EpiVax, Inc.
    Inventors: Anne De Groot, William Martin, Daniel S. Rivera
  • Antigenic peptides for prevention and treatment of cancer
    Patent number: 12016910
    Abstract: The present invention relates to antigen-based immunotherapy, in particular cancer immunotherapy. In particular, the present invention provides antigenic peptides, which are distinct from, but have amino acid similarity to, fragments of human tumor antigens. The present invention further provides immunogenic compounds, nanoparticles, cells and pharmaceutical compositions comprising such antigenic peptides and nucleic acids encoding such antigenic peptides.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: June 25, 2024
    Assignee: ENTEROME S.A.
    Inventors: Laurent Chene, Christophe Bonny, Francesco Strozzi
  • Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer
    Patent number: 12016911
    Abstract: Combination therapeutics for the treatment of cancer include the use of immune effector cells, IL-15 based superagonists and one or more immunotherapeutic agents such as Bacillus Calmette-Guerin (BCG).
    Type: Grant
    Filed: November 15, 2023
    Date of Patent: June 25, 2024
    Assignee: NantCell, Inc.
    Inventor: Patrick Soon-Shiong
  • Compositions comprising recombinant cells and an insecticide
    Patent number: 12016912
    Abstract: The present invention relates to a composition comprising a) recombinant exosporium-producing Bacillus cells that express a fusion protein comprising: (i) at least one plant growth stimulating protein or peptide and (ii) a targeting sequence that localizes the fusion protein to the exosporium of the Bacillus cells; and b) at least one particular insecticide disclosed herein in a synergistically effective amount. Furthermore, the present invention relates to the use of this composition as well as a method for enhancing plant growth, promoting plant health, and/or reducing overall damage of plants and plant parts.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: June 25, 2024
    Assignees: Bayer CropScience LP, Spogen Biotech Inc.
    Inventors: Damian Curtis, Brian Thompson
  • Immunogenic compositions and uses thereof
    Patent number: 12016913
    Abstract: The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
    Type: Grant
    Filed: September 14, 2021
    Date of Patent: June 25, 2024
    Assignee: Pfizer Inc.
    Inventors: Annaliesa Sybil Anderson, Leena Shriram Bagle, Amardeep Singh Bhupender Bhalla, Miguel Angel Garcia, Lei Hu, Lakshmi Khandke, Avvari Krishna Prasad, Cindy Xudong Yang
  • Compositions comprising polysaccharide-protein conjugates and methods of use thereof
    Patent number: 12016914
    Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and/or pneumococcal diseases caused by S. pneumoniae.
    Type: Grant
    Filed: March 23, 2023
    Date of Patent: June 25, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Chitrananda Abeygunawardana, Yadong Adam Cui, Romulo Ferrero, Jian He, Luwy Musey, Tanaz Petigara, Julie M. Skinner
  • Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
    Patent number: 12016915
    Abstract: The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.
    Type: Grant
    Filed: November 9, 2021
    Date of Patent: June 25, 2024
    Assignee: BAYLOR RESEARCH INSTITUTE
    Inventors: SangKon Oh, Dapeng Li, Jacques Banchereau, Gerard Zurawski, Sandra Zurawski
  • Nant COVID vaccine cross reactivity
    Patent number: 12016916
    Abstract: Recombinant SARS-CoV2 vaccine compositions and methods are presented that have unexpected cross-reactivity against a variety of other coronaviruses, and particularly against SARS-CoV1, MFRS-CoV, OC43-CoV, and HKU1-CoV in addition to significant reactivity against SARS-CoV2A. Moreover, the vaccine compositions presented herein also produced cross-reactive memory B cells as well as cross-reactive memory T cells with cross-reactivity spanning a relatively wide range of different coronaviruses.
    Type: Grant
    Filed: December 7, 2023
    Date of Patent: June 25, 2024
    Assignee: ImmunityBio, Inc.
    Inventor: Patrick Soon-Shiong
  • Peanut formulations and uses thereof
    Patent number: 12016917
    Abstract: The present application relates to compositions for oral immunotherapy of peanut allergies. Further, the present application relates to methods for the preparation of the compositions for immunotherapy, and their use in immunotherapy.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: June 25, 2024
    Assignee: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
    Inventors: Bryan Walser, Howard V. Raff
  • Peptide-containing adjuvant compounds having peg spacers
    Patent number: 12016918
    Abstract: Adjuvant compounds are described, as well as their conjugates comprising peptide antigens or other immunomodulatory moieties. Also described are methods of modulating immune responses in a subject in need thereof, as well as methods of treating cancer, viral or bacterial infections comprising administering the adjuvant compounds or the conjugates to a subject in need thereof.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: June 25, 2024
    Assignees: UNIVERSITEIT LEIDEN, ACADEMISCH ZIEKENHUIS LEIDEN
    Inventors: Dmitri V. Filippov, Geoffroy P. P. Gential, Gijsbert Van Der Marel, Ferry Ossendorp
  • Methods for manufacturing an adjuvant
    Patent number: 12016919
    Abstract: The present invention relates to compositions and methods for manufacturing an adjuvant comprising a saponin using a microfluidic device and to aspects thereof.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: June 25, 2024
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Pol Harvengt, Philippe Jehoulet, Loic Le Gourrierec, Demostene Sifakakis, Laurent Strodiot
  • Adjuvant based on peptide nucleic acid
    Patent number: 12016920
    Abstract: Provided are an adjuvant useful for preparing a vaccine having high efficacy and high safety, and a vaccine composition comprising the adjuvant. The adjuvant comprises a peptide nucleic acid to which a cell penetrating peptide is bound.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: June 25, 2024
    Assignee: DENKA COMPANY LIMITED
    Inventors: Ryotaro Mitsumata, Asumi Kanda
  • Methods for treatment of psoriasis with an anti-Apo B100 antibody
    Patent number: 12016921
    Abstract: Compositions and methods for treating a subject with psoriasis are provided, including an inhibitor of oxidized low density lipoprotein (LDL), malondialdehyde-modified epitope in LDL or native LDL for administration. Exemplary inhibitors of oxidized or malondialdehyde-modified LDL include orticumab, a variant antibody or peptides capable of binding oxidized or malondialdehyde-modified LDL, which results in improvement in conditions of psoriasis even in patients that are refractory to ultraviolet A/B therapy and topical steroids.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: June 25, 2024
    Assignee: Abcentra, LLC
    Inventors: Bertrand C. Liang, Stacey Ruiz, Christopher John Farina
  • Stabilized aqueous antibody compositions
    Patent number: 12016922
    Abstract: The present invention provides an aqueous solution comprising an antibody protein at a concentration of at least about 10 mg/mL and an oligomer of ethyleneimine, wherein the number of repeating units of ethyleneimine (n) in the oligomer is in the range of n=2-12.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: June 25, 2024
    Assignee: Arecor Limited
    Inventors: Jan Jezek, Guy Casy, Barry Derham, Nikki Royle
  • Claudin 18.2 T cell-antigen couplers and uses thereof
    Patent number: 12016923
    Abstract: Claudin 18.2 T cell antigen couplers (TACs) polypeptides having (i) an antigen-binding domain that binds Claudin 18.2, (ii) an antigen-binding domain that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide are provided. Nucleic acids encoding the claudin 18/2 TACs are also provided.
    Type: Grant
    Filed: June 1, 2022
    Date of Patent: June 25, 2024
    Assignee: Triumvira Immunologics USA, Inc.
    Inventors: Andreas Bader, Christopher W. Helsen, Philbert Ip, Tania Benatar, Ling Wang
  • Composition for patch preparation comprising drug, organic solvent, lipophilic mass base, and powder
    Patent number: 12016924
    Abstract: A non-aqueous patch preparation may include a drug solution in which a drug is dissolved in an organic solvent, a lipophilic mass base, and anhydrous silicic acid powders that are insoluble both in the organic solvent and in the lipophilic mass base. The organic solvent is selected from the group consisting of propylene glycol, 1,3-butanediol, polyethylene glycol, and propylene carbonate. The lipophilic mass base comprises an elastomer, a tackifier, and a softening agent wherein the elastomer is styrene-isoprene-styrene copolymer (SIS). The patch preparation has 2% to 10% by weight of the anhydrous silicic acid powders.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: June 25, 2024
    Assignee: MEDRX CO., LTD.
    Inventors: Hidetoshi Hamamoto, Katsuhiro Yamanaka, Takahiro Tanimoto
  • Carbohydrate composition as pharmaceutical ingredient and use thereof
    Patent number: 12016925
    Abstract: A carbohydrate composition includes fucose, glucuronic acid, galactose, and arabinose. Based on the total weight of the carbohydrate composition, the content of fucose is 45.5% to 76% by weight; the content of glucuronic acid is 11% to 19% by weight; the content of galactose is 4.5% to 14.5% by weight, and the content of arabinose is 5.5% to 18% by weight. A pharmaceutical ingredient including the above-mentioned carbohydrate composition is provided.
    Type: Grant
    Filed: February 7, 2022
    Date of Patent: June 25, 2024
    Assignees: Medgaea Japan Co., Ltd., Medgaea Life Sciences Ltd.
    Inventors: Chang-Jer Wu, Bo-Rui Chen, Chih-Chun Hong, Yuh-Ting Huang, Masahiko Iha, Makoto Tomori
  • Terpolymers and their use in pharmaceutical dosage forms
    Patent number: 12016926
    Abstract: Terpolymer, wherein 20 to 35% by weight of the structural units are derived from acrylic acid, 45 to 60% by weight of the structural units from a hydrophobic methacrylate selected from a group consisting of isopropyl methacrylate, tert-butyl methacrylate and cyclohexyl methacrylate and 15 to 40% by weight of the structural units from a third olefinic monomer selected from the group consisting of N-vinyl lactam, hydroxy ethyl methacrylate and phenoxyethyl acrylate with the proviso that the total amount of structural units derived from the three monomer groups adds up to 100% by weight, and the use of the terpolymers as crystallization inhibitors in pharmaceutical dosage forms for inhibiting the recrystallization in an aqueous environment of a human or animal body of an active ingredient.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: June 25, 2024
    Assignee: BASF SE
    Inventors: Ferdinand Paul Brandl, Theo Smit, Felicitas Guth, Karl Kolter, Maximilian Angel, Frank Schmidt
  • Injectable preparation
    Patent number: 12016927
    Abstract: An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s?1 end having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1.000 s?1, as measured.
    Type: Grant
    Filed: December 30, 2022
    Date of Patent: June 25, 2024
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Daiki Kaneko, Takakuni Matsuda, Yusuke Hoshika
  • Composition as auxiliary means for oral medication
    Patent number: 12016928
    Abstract: Compositions, specifically a jelly, are provided the use of which composition as an auxiliary means eases the taking of oral medication in solid form, which composition comprises iota-carrageenan as a jellifying agent and citric acid as a salivating agent, characterized in that the composition further comprises maltodextrin. In another aspect, the composition comprises a calcium sequestrant for adjusting Ca-ion activity of the composition. In one embodiment, the composition comprises iota-carrageenan in 0.7-1.0% in mass, citric acid in 0.06-0.07% in mass, maltodextrin in 1.5% in mass, all relative to the total mass of the composition, and an amount of a calcium sequestrant such that the Ca-ion activity of the composition is between 20 ppm and 80 ppm.
    Type: Grant
    Filed: July 13, 2022
    Date of Patent: June 25, 2024
    Assignee: PAXTREE LTD.
    Inventor: Ron Bruijns
  • Lipid formulations for delivery of therapeutic agents
    Patent number: 12016929
    Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.
    Type: Grant
    Filed: January 12, 2024
    Date of Patent: June 25, 2024
    Assignee: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Ed Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
  • Skin-permeating carrier containing nucleic acid complex and use thereof
    Patent number: 12016930
    Abstract: A skin-penetrating carrier containing a nucleic acid complex having a novel structure which introduces a bioactive nucleic acid into cells. Composition for diagnosing, preventing or treating disease and to a skin-penetrating carrier containing a nucleic acid complex in which a bioactive nucleic acid and a carrier peptide nucleic acid are complementarily bound to each other, and having skin permeability and skin retention ability. Skin-penetrating carrier containing nucleic acid complex having structure of Structural Formula (1) has both a skin penetration function of effectively delivering a large-molecular-weight drug and in vivo effectiveness. Carrier enables bioactive nucleic acids or various compounds to pass through the epidermis and dermis of the skin, thus enables external treatment by application to the skin surface.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: June 25, 2024
    Assignee: SEASUN THERAPEUTICS, INC.
    Inventors: Hye Joo Kim, Ji-Yeon Yu, Dong In Lee, Yusun Kang, Hee Kyung Park
  • Nanoparticles comprising peptides including an n-terminal linker
    Patent number: 12016931
    Abstract: The present invention provides nanoparticles comprising: (a) an amphiphilic polymer with a number average molecular weight (Mn) of 20,000 g/mol or less; and (b) a peptide that is covalently linked to the polymer, wherein the peptide comprises 8 to 50 amino acids, including an N-terminal linker sequence comprising at least one Arg amino acid residue and a sequence comprising an MHC binding sequence comprising a T cell receptor epitope. The present invention further comprises compositions comprising respective nanoparticles and a liquid or lyophilized carrier as well as nanoparticles and compositions of the invention for use in inducing tolerance to a therapeutic compound (protein, viral vector, lipid vesicle), an allergen or to an autoantigen or for treating an allergy, an autoimmune disease, an exogenous antigen (transplantation antigens, drugs) or a food intolerance.
    Type: Grant
    Filed: July 26, 2023
    Date of Patent: June 25, 2024
    Assignee: Topas Therapeutics GmbH
    Inventors: Johannes Pohlner, Reinaldo Digigow, Barbara Metzler, Sabine Fleischer
  • Gene editing for hemophilia A with improved factor VIII expression
    Patent number: 12016932
    Abstract: Provided herein, in some embodiments, are materials and methods for treating hemophilia A in a subject ex vivo or in vivo. Also provided herein, in some embodiments, are materials and methods for knocking in a coding sequence encoding a synthetic FVIII having a B domain substitute into a genome.
    Type: Grant
    Filed: November 15, 2022
    Date of Patent: June 25, 2024
    Assignees: CRISPR THERAPEUTICS AG, BAYER HEALTHCARE LLC
    Inventor: Alan Richard Brooks
  • Method for stimulating axonal regeneration
    Patent number: 12016933
    Abstract: A method of promoting axonal regeneration can include directing neuronal lipid synthesis away from triglyceride synthesis and toward phospholipid synthesis. The method can include administering to the patient a therapeutically effective amount of an inhibitor compound selected from the group consisting of a Lipin-1 inhibitor, a diglyceride acyltransferase inhibitor, and combinations thereof or administering a gene editing therapy to the patient that reduces expression of LIPIN1 or a diglyceride acyltransferase gene.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: June 25, 2024
    Assignee: THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Chao Yang, Xu Wang, Kai Liu
  • Animal model for SARS-CoV-2-spike induced coagulopathy
    Patent number: 12016934
    Abstract: Described herein is an animal model useful for identifying therapeutic agents that can inhibit the physiological effects or symptoms of COVID-19 infection, including the effects of the following on one or more organs of the animal: inflammation, oxidative stress, fibrin deposition, blood brain barrier breakdown, clotting, and vascular problems.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: June 25, 2024
    Assignee: The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
    Inventors: Katerina Akassoglou, Warner Greene, Jae Kyu Ryu, Mauricio Montano
  • Methods for detecting CCR2 receptors
    Patent number: 12016935
    Abstract: Among the various aspects of the present disclosure is the provision of compositions of imaging agents and methods for use in detecting, monitoring, and evaluating CCR2 associated diseases, disorders, and conditions.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: June 25, 2024
    Assignee: Washington University
    Inventors: Yongjian Liu, Robert Gropler, Steven Brody, Daniel Kreisel
  • Neovascular-targeting contrast medium composition and method for preparing same
    Patent number: 12016936
    Abstract: The present invention relates to a neovascular-targeting contrast medium composition and a method for preparing same. The neovascular-targeting contrast medium composition according to the present invention exhibits high binding force to neovascularization-associated ?v?3 integrin, excellent tissue permeability and biostability, enables simple measurement in vitro, in vivo, or ex vivo, and thus is effective in the detection of neovascularization and in diagnosing diseases associated therewith, and therefore may be usefully employed in the relevant industries.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: June 25, 2024
    Assignee: KOREA BASIC SCIENCE INSTITUTE
    Inventors: Ki-Yuk Chang, Chan-Woo Kim, Kwan-Soo Hong, Hyun-Seung Lee, Hyun-Min Kim
  • Composition of radioactive and non-radioactive microparticles
    Patent number: 12016937
    Abstract: The present disclosure provides a composition that includes a mixture of (i) radioactive microparticles; and (ii) non-radioactive microparticles. The radioactive microparticles may be suitable to treat a vascularized tumour, such as a liver tumour or a metastasized liver tumour. The radioactive microparticles and the non-radioactive microparticles may have substantially the same resistance when flowing in a liquid through a conduit. The present disclosure also provides methods of making and methods of using mixtures of microparticles.
    Type: Grant
    Filed: September 15, 2020
    Date of Patent: June 25, 2024
    Assignee: ABK BIOMEDICAL INCORPORATED
    Inventors: Marc Gregoire, F. Anthony Headley, Jr.
  • Pulp regeneration compositions and methods of forming and using the same
    Patent number: 12016938
    Abstract: A dental tissue regenerative composition. The composition includes a combination of (1) human dental pulp stem cells and (2) at least one of human umbilical vein endothelial cells or vascular endothelial growth factor. The combination is encapsulated in a light-activated gelatin methacrylate hydrogel.
    Type: Grant
    Filed: October 20, 2022
    Date of Patent: June 25, 2024
    Assignees: TRUSTEES OF TUFTS COLLEGE, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Pamela C. Yelick, Ali Khademhosseini
  • Skin treatment methods and compositions for transdermal delivery of active agents
    Patent number: 12016939
    Abstract: Disclosed are stable, non-irritating, skin treatment active agents containing formulations and delivery systems for topical application to the skin. The disclosed topical formulations and delivery systems provide controlled, gentle release of the active agents into the skin for the treatment of amenable skin conditions as well as for improvement of aesthetic skin properties. Also provided are methods for the formulation, manufacture and use of the disclosed formulations and delivery systems.
    Type: Grant
    Filed: February 22, 2023
    Date of Patent: June 25, 2024
    Assignee: Topix Pharmaceuticals, Inc.
    Inventor: Steven M. Hernandez
  • Dentifrice comprising a PVM-MA copolymer and a source of free fluoride ions
    Patent number: 12016940
    Abstract: A dentifrice composition is described comprising a source of free fluoride ions; and from 0.1% to less than 0.5% by weight of the composition of a copolymer of methyl vinyl ether with maleic anhydride or acid; and wherein the composition has a slurry pH from 6.0 to 7.5, and wherein the composition is free of a carboxylic acid or alkali metal salt thereof wherein the acid is selected from the group consisting of malonic acid, glutaric acid, tartaric acid, lactic acid and mixtures thereof. The composition enhances fluoride uptake into teeth and provides protection against acidic challenges.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: June 25, 2024
    Assignee: HALEON UK IP LIMITED
    Inventor: Shazada Yassar Khan